ABIVAX Société Anonyme (NASDAQ:ABVX) Receives "Market Outperform" Rating from JMP Securities

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock had its "market outperform" rating reissued by analysts at JMP Securities in a report released on Friday,Benzinga reports. They presently have a $33.00 target price on the stock. JMP Securities' target price indicates a potential upside of 417.24% from the company's previous close.

Separately, Citizens Jmp raised shares of ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ABIVAX Société Anonyme presently has a consensus rating of "Buy" and a consensus price target of $38.67.

ABIVAX Société Anonyme Trading Down 4.5 %

NASDAQ:ABVX traded down $0.30 during mid-day trading on Friday, hitting $6.38. 211,089 shares of the company's stock were exchanged, compared to its average volume of 145,215. ABIVAX Société Anonyme has a one year low of $6.26 and a one year high of $17.02. The business has a fifty day moving average price of $8.38 and a 200 day moving average price of $10.46.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several hedge funds and other institutional investors have recently bought and sold shares of ABVX. GAMMA Investing LLC purchased a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at approximately $29,000. BNP Paribas Financial Markets raised its stake in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after buying an additional 5,900 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after buying an additional 80,807 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after buying an additional 119,300 shares during the last quarter. Finally, abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Institutional investors own 47.91% of the company's stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.